Ana Colado
Academia Nacional de Medicina
23 Papers
6 Citations
Ana Colado is an academic researcher from Academia Nacional de Medicina. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 7, co-authored 17 publications. Previous affiliations of Ana Colado include New York Academy of Medicine.
Chat about Author
Papers
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge,María Belén Almejún,Enrique Podaza,Ana Colado,Horacio Fernandez Grecco,María Cabrejo,Raimundo F. Bezares,Mirta Giordano,Romina Gamberale +8 more
TL;DR: Ibrutinib is an oral irreversible inhibitor of the bruton tyrosine kinase (Btk) which has shown promising efficacy and excellent tolerability in patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies.
65
The mucosal surfaces of both eyes are immunologically linked by a neurogenic inflammatory reflex involving TRPV1 and substance P
Mauricio Guzman,Maximiliano S Miglio,Nadia R Zgajnar,Ana Colado,María B Almejún,Irene Angélica Keitelman,Florencia Sabbione,Federico Fuentes,Analía Silvina Trevani,Analía Silvina Trevani,Mirta Giordano,Mirta Giordano,Jeremias Gaston Galletti +12 more
TL;DR: Both ocular surfaces are immunologically linked and suggests potential therapeutic targets for intervention as well as pharmacological inhibitors and agonists used to identify transient receptor potential vanilloid 1 (TRPV1) channel as the receptor sensing tissue damage in the injured eye and substance P released in the opposite ocular surface as the effector of the sympathetic response.
32
The effect of ibrutinib on neutrophil and γδ T cell functions.
Denise Risnik,Denise Risnik,Esteban Enrique Elías,Irene Angélica Keitelman,Ana Colado,Enrique Podaza,Gregorio Cordini,Gregorio Cordini,Maricef Vergara Rubio,Maricef Vergara Rubio,Horacio Fernandez Grecco,Raimundo F. Bezares,Mercedes Borge,Mercedes Borge,Analía Silvina Trevani,Analía Silvina Trevani,Mirta Giordano,Mirta Giordano,Carolina Jancic,Carolina Jancic,Romina Gamberale,Romina Gamberale +21 more
TL;DR: In vitro ibrutinib reduces the production of reactive oxygen species (ROS) and bacteria killing capacity, and slightly impairs neutrophil extracellular traps (NETs) production without affecting bacteria-uptake and CD62L-downregulation induced by fMLP or aggregated IgG.
19
In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia.
Alexia Vereertbrugghen,Ana Colado,Ernesto Gargiulo,Raimundo F. Bezares,Horacio Fernandez Grecco,Gregorio Cordini,Gregorio Cordini,Maria del Rosario Custidiano,Jean-Hugues François,Guy Berchem,Mercedes Borge,Mercedes Borge,Jérôme Paggetti,Etienne Moussay,Romina Gamberale,Romina Gamberale,Mirta Giordano,Mirta Giordano,Pablo Elías Morande +18 more
TL;DR: Venetoclax (ABT-199) is a Bcl-2 inhibitor currently approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in adult patients ineligible for intensive chemotherapy as mentioned in this paper.
The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients
Ana Colado,María Belén Almejún,María Belén Almejún,Enrique Podaza,Denise Risnik,Carmen Stanganelli,Esteban Enrique Elías,Patricia Carolina Dos Santos,Irma Slavutsky,Horacio Fernandez Grecco,María Cabrejo,Raimundo F. Bezares,Mirta Giordano,Mirta Giordano,Romina Gamberale,Romina Gamberale,Mercedes Borge,Mercedes Borge +17 more
TL;DR: Results suggest that in CLL patients treated with R406 or GS-9973 T cell functions, as well as macrophage-mediated anti-tumor activity of rituximab, might be impaired.
16